Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.95
SNSS's Cash-to-Debt is ranked lower than
67% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. SNSS: 2.95 )
Ranked among companies with meaningful Cash-to-Debt only.
SNSS' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.18  Med: 13.39 Max: No Debt
Current: 2.95
Equity-to-Asset 0.49
SNSS's Equity-to-Asset is ranked lower than
69% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SNSS: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
SNSS' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.09  Med: 0.51 Max: 0.87
Current: 0.49
-2.09
0.87
Piotroski F-Score: 3
Altman Z-Score: -18.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1437.70
SNSS's Operating Margin % is ranked lower than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. SNSS: -1437.70 )
Ranked among companies with meaningful Operating Margin % only.
SNSS' s Operating Margin % Range Over the Past 10 Years
Min: -64863.64  Med: -745.14 Max: -399.36
Current: -1437.7
-64863.64
-399.36
Net Margin % -1499.33
SNSS's Net Margin % is ranked lower than
81% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. SNSS: -1499.33 )
Ranked among companies with meaningful Net Margin % only.
SNSS' s Net Margin % Range Over the Past 10 Years
Min: -74506.06  Med: -909.61 Max: -401.09
Current: -1499.33
-74506.06
-401.09
ROE % -237.77
SNSS's ROE % is ranked lower than
91% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. SNSS: -237.77 )
Ranked among companies with meaningful ROE % only.
SNSS' s ROE % Range Over the Past 10 Years
Min: -1585.52  Med: -167.56 Max: -57.33
Current: -237.77
-1585.52
-57.33
ROA % -100.05
SNSS's ROA % is ranked lower than
83% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. SNSS: -100.05 )
Ranked among companies with meaningful ROA % only.
SNSS' s ROA % Range Over the Past 10 Years
Min: -448.13  Med: -81.16 Max: -39.99
Current: -100.05
-448.13
-39.99
ROC (Joel Greenblatt) % -432166.67
SNSS's ROC (Joel Greenblatt) % is ranked lower than
99% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. SNSS: -432166.67 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNSS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -432166.67  Med: -46443.7 Max: -859.84
Current: -432166.67
-432166.67
-859.84
3-Year Revenue Growth Rate -43.80
SNSS's 3-Year Revenue Growth Rate is ranked lower than
83% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. SNSS: -43.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNSS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -90.9  Med: -43.8 Max: 385.2
Current: -43.8
-90.9
385.2
3-Year EBITDA Growth Rate -14.00
SNSS's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. SNSS: -14.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNSS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -59.6  Med: -35.2 Max: 16.2
Current: -14
-59.6
16.2
3-Year EPS without NRI Growth Rate -15.10
SNSS's 3-Year EPS without NRI Growth Rate is ranked lower than
66% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SNSS: -15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNSS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.4  Med: -17.9 Max: 21
Current: -15.1
-60.4
21
GuruFocus has detected 3 Warning Signs with Sunesis Pharmaceuticals Inc $SNSS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNSS's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SNSS Guru Trades in Q1 2016

Jim Simons 70,036 sh (New)
» More
Q2 2016

SNSS Guru Trades in Q2 2016

First Eagle Investment 1,500,000 sh (New)
Jim Simons 272,326 sh (+288.84%)
» More
Q3 2016

SNSS Guru Trades in Q3 2016

Jim Simons 94,581 sh (+108.38%)
First Eagle Investment 249,999 sh (unchged)
» More
Q4 2016

SNSS Guru Trades in Q4 2016

First Eagle Investment 574,999 sh (+130.00%)
Jim Simons 110,581 sh (+16.92%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BDSI, NAS:CASC, AMEX:BTX, NAS:BSTC, NAS:ANIP, NAS:BCRX, NAS:BMRN » details
Traded in other countries:RYIP.Germany,
Sunesis Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers.

Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, most commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.

Ratios

vs
industry
vs
history
PB Ratio 39.43
SNSS's PB Ratio is ranked lower than
97% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. SNSS: 39.43 )
Ranked among companies with meaningful PB Ratio only.
SNSS' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.8 Max: 278.91
Current: 39.43
1.01
278.91
PS Ratio 24.45
SNSS's PS Ratio is ranked lower than
62% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. SNSS: 24.45 )
Ranked among companies with meaningful PS Ratio only.
SNSS' s PS Ratio Range Over the Past 10 Years
Min: 1.1  Med: 18.67 Max: 936
Current: 24.45
1.1
936
Current Ratio 3.95
SNSS's Current Ratio is ranked lower than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SNSS: 3.95 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 3.74 Max: 7.2
Current: 3.95
1.19
7.2
Quick Ratio 3.95
SNSS's Quick Ratio is ranked higher than
51% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SNSS: 3.95 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s Quick Ratio Range Over the Past 10 Years
Min: 1.19  Med: 3.74 Max: 7.2
Current: 3.95
1.19
7.2

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.20
SNSS's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SNSS: -32.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNSS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -197.7  Med: -32.2 Max: -6.2
Current: -32.2
-197.7
-6.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.31
SNSS's Price-to-Net-Cash is ranked higher than
66% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. SNSS: 4.31 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SNSS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.9  Med: 3.35 Max: 33.5
Current: 4.31
1.9
33.5
Price-to-Net-Current-Asset-Value 38.00
SNSS's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. SNSS: 38.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SNSS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.85  Med: 3.26 Max: 38.27
Current: 38
1.85
38.27
Price-to-Tangible-Book 38.00
SNSS's Price-to-Tangible-Book is ranked lower than
96% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SNSS: 38.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SNSS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64  Med: 3.08 Max: 38.77
Current: 38
1.64
38.77
Price-to-Median-PS-Value 1.31
SNSS's Price-to-Median-PS-Value is ranked lower than
66% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. SNSS: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNSS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.86 Max: 50.59
Current: 1.31
0.05
50.59
Earnings Yield (Greenblatt) % -46.51
SNSS's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. SNSS: -46.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNSS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47.39  Med: 649.3 Max: 32725
Current: -46.51
-47.39
32725

More Statistics

Revenue (TTM) (Mil) $2.54
EPS (TTM) $ -2.44
Beta1.14
Short Percentage of Float0.54%
52-Week Range $2.63 - 6.30
Shares Outstanding (Mil)20.93

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 2 8
EPS ($) -2.28 -1.90
EPS without NRI ($) -2.28 -1.90
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
Roundys Among Largest Insiders' Buys of the Week Dec 31 2015 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Jul 28 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference Mar 28 2017
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 27 2017
Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding... Mar 22 2017
Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
SUNESIS PHARMACEUTICALS INC Financials Mar 15 2017
Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Edited Transcript of SNSS earnings conference call or presentation 9-Mar-17 4:00pm GMT Mar 10 2017
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 09 2017
Sunesis reports 4Q loss Mar 09 2017
Sunesis reports 4Q loss Mar 09 2017
Q4 2016 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open Mar 09 2017
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Recent... Mar 09 2017
Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug Mar 08 2017
GlaxoSmithKline's Nucala Positive in Label Expansion Study Mar 07 2017
Sunesis to Host Conference Call on March 9th to Discuss Fourth Quarter and Full-Year 2016 Financial... Mar 02 2017
Sunesis Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference Mar 01 2017
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Feb 27 2017
Emergent (EBS) Beats Earnings, Revenue Estimates in Q4 Feb 24 2017
Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line Feb 23 2017
Pfizer's Leukemia Candidate Gets Priority Review in U.S. Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)